Abstract
Ion Channel-Target Toxicology
Highlights
Nowadays, a representative instance comes from the successfully commercialized toxin product “Ziconotide,” developed by Eli Lilly Incorporated (USA), from the venom of Conus
On the other side, JZMed Incorporated, a worldwide renowned market research firm specialized in the Chinese pharmaceutical industry, once forecasted that the Chinese preclinical and toxicology outsourcing industry would likely grow in a compound annual growth rate of 27% in five years after 2010 and its market value would likely reach more than $760 million by 2015
The hindrances toward toxin-drug transformation may include but not be limited to (1) overall costs of drug development; (2) elimination of nondevelopable drug candidates; (3) extensive toxicology and safety pharmacology researches for any drug candidates
Summary
A representative instance comes from the successfully commercialized toxin product “Ziconotide,” developed by Eli Lilly Incorporated (USA), from the venom of Conus. It has been well documented that ion channels are specific targets for numerous toxins.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
